Q/C Technologies, Inc. Cost of Revenue
Q/C Technologies, Inc. (QCLS) reported Cost of Revenue of $46.53 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-25.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2020-03-25
- Q/C Technologies, Inc. cost of revenue for the quarter ending 2019-12-31 was $8.05K, a 23.25% decline year-over-year.
- Q/C Technologies, Inc. cost of revenue for the quarter ending 2019-09-30 was $10.99K, a 39.37% decline year-over-year.
- Q/C Technologies, Inc. cost of revenue for the quarter ending 2019-06-30 was $15.66K, a 58.78% decline year-over-year.
- Q/C Technologies, Inc. cost of revenue for the quarter ending 2019-03-31 was $11.92K, a 55.76% decline year-over-year.
- Q/C Technologies, Inc. cost of revenue for fiscal 2019 was $46.53K, a 50.26% decline from fiscal 2018.
- Q/C Technologies, Inc. cost of revenue for fiscal 2018 was $93.56K, a 31.28% decline from fiscal 2017.
- Q/C Technologies, Inc. cost of revenue for fiscal 2017 was $136.15K, a 1.82% decline from fiscal 2016.
- Q/C Technologies, Inc. cost of revenue for fiscal 2016 was $138.66K, a 20.13% increase from fiscal 2015.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|---|---|
| 2019-12-31 | $8.05K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $19.05K derived: sum of 2 quarters · filed 2020-03-25 | $34.70K derived: sum of 3 quarters · filed 2020-03-25 | $46.53K 10-K · filed 2020-03-25 | ||
| 2019-09-30 | $10.99K 10-Q · filed 2019-11-14 | $26.65K derived: sum of 2 quarters · filed 2019-11-14 | $38.48K 10-Q · filed 2019-11-14 | $49.06K derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2019-06-30 | $15.66K 10-Q · filed 2019-08-14 | $27.58K 10-Q · filed 2019-08-14 | $38.07K derived: sum of 3 quarters · filed 2020-03-25 | $56.20K derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2019-03-31 | $11.92K 10-Q · filed 2019-05-20 | $22.41K derived: sum of 2 quarters · filed 2020-03-25 | $40.54K derived: sum of 3 quarters · filed 2020-03-25 | $78.53K derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2018-12-31 | $10.49K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $28.62K derived: sum of 2 quarters · filed 2020-03-25 | $66.61K derived: sum of 3 quarters · filed 2020-03-25 | $93.56K 10-K · filed 2020-03-25 | ||
| 2018-09-30 | $18.13K 10-Q · filed 2019-11-14 | $56.12K derived: sum of 2 quarters · filed 2019-11-14 | $83.06K 10-Q · filed 2019-11-14 | $155.49K derived: sum of 4 quarters · filed 2019-11-14 | ||
| 2018-06-30 | $37.99K 10-Q · filed 2019-08-14 | $64.94K 10-Q · filed 2019-08-14 | $137.36K derived: sum of 3 quarters · filed 2019-08-14 | $153.51K derived: sum of 4 quarters · filed 2019-08-14 | ||
| 2018-03-31 | $26.94K 10-Q · filed 2019-05-20 | $99.37K derived: sum of 2 quarters · filed 2019-05-20 | $115.52K derived: sum of 3 quarters · filed 2019-05-20 | $146.91K derived: sum of 4 quarters · filed 2019-05-20 | ||
| 2017-12-31 | $72.43K derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $88.57K derived: sum of 2 quarters · filed 2019-04-01 | $119.97K derived: sum of 3 quarters · filed 2019-04-01 | $136.15K 10-K · filed 2019-04-01 | ||
| 2017-09-30 | $16.15K 10-Q · filed 2018-11-14 | $47.54K derived: sum of 2 quarters · filed 2018-11-14 | $63.72K 10-Q · filed 2018-11-14 | $113.95K derived: sum of 4 quarters · filed 2018-11-14 | ||
| 2017-06-30 | $31.39K 10-Q · filed 2018-08-14 | $47.57K 10-Q · filed 2018-08-14 | $47.57K 10-Q · filed 2017-08-14 | $97.81K derived: sum of 3 quarters · filed 2018-08-14 | $117.50K derived: sum of 4 quarters · filed 2018-08-14 | |
| 2017-03-31 | $16.18K 10-Q · filed 2018-07-13 | $66.41K derived: sum of 2 quarters · filed 2018-07-13 | $86.11K derived: sum of 3 quarters · filed 2018-07-13 | $133.13K derived: sum of 4 quarters · filed 2018-07-13 | ||
| 2016-12-31 | $50.23K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2018-07-13 | $69.93K derived: sum of 2 quarters · filed 2018-07-13 | $116.95K derived: sum of 3 quarters · filed 2018-07-13 | $138.66K 10-K/A · filed 2018-07-13 | ||
| 2016-09-30 | $19.70K 10-Q/A · filed 2018-07-13 | $19.42K 10-Q · filed 2016-11-14 | $66.71K derived: sum of 2 quarters · filed 2018-07-13 | $88.43K 10-Q/A · filed 2018-07-13 | $120.85K derived: sum of 4 quarters · filed 2018-07-13 | |
| 2016-06-30 | $47.02K 10-Q/A · filed 2018-07-13 | $68.73K 10-Q/A · filed 2018-07-13 | $101.16K derived: sum of 3 quarters · filed 2018-07-13 | $116.75K derived: sum of 4 quarters · filed 2018-07-13 | ||
| 2016-03-31 | $21.71K 10-Q · filed 2017-05-15 | $54.14K derived: sum of 2 quarters · filed 2017-05-15 | $69.73K derived: sum of 3 quarters · filed 2017-05-15 | $92.45K derived: sum of 4 quarters · filed 2017-05-15 | ||
| 2015-12-31 | $32.43K derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-11 | $48.02K derived: sum of 2 quarters · filed 2017-04-11 | $70.73K derived: sum of 3 quarters · filed 2017-04-11 | $115.42K 10-K · filed 2017-04-11 | ||
| 2015-09-30 | $15.59K 10-Q · filed 2016-11-14 | $38.31K derived: sum of 2 quarters · filed 2016-11-14 | $83.00K 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | $22.72K 10-Q · filed 2016-08-11 | $67.41K 10-Q · filed 2016-08-11 | ||||
| 2015-03-31 | $44.69K 10-Q · filed 2016-05-12 | |||||
| 2014-12-31 | $71.42K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |